Uterine fibroids and endometriosis are common gynecologic diseases that often cause pain, distress, and decreased quality of life. Unfortunately, they are often dismissed by clinicians as minor conditions. Traditional treatment options have included surgery, hormone therapy, radiation, and medical therapies. But now, gonadotropin-releasing hormone (GnRH) antagonists are proving to be an effective and well-tolerated alternative to invasive procedures. This real-world simulation reviews these emerging therapies and approaches for aligning patient priorities and desires with individualized treatment options.
Real-World Scenarios in Uterine Fibroids and Endometriosis: Diagnosis, Assessment, & the Role of GnRH Antagonists
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Real-World Scenarios in Uterine Fibroids and Endometriosis: Diagnosis, Assessment, and the Role of GnRH Antagonists
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
Overview
Disclosure of Conflicts of Interest
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Erin T. Carey, MD, MSCR
Receipt of intellectual property right/patent holder: Patent applications for vestibulodynia and myofascial pelvic pain through UNC
Other: Served as an expert witness for pelvic pain and surgical complicationsErica E. Marsh, MD, MSCI, FACOG
Consulting fees/advisory boards: Myovant Sciences Ltd, Pfizer IncThe peer reviewers and activity planners have no financial relationships to disclose.
Target Audience
This activity is intended for obstetrician-gynecologists, primary care physicians, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with uterine fibroids and/or endometriosis.
Learning Objectives
Upon completion, participants should be able to:
- Recognize the signs, symptoms, patient characteristics, and comorbidities that are associated with UF and endometriosis
- Evaluate the benefits and limitations of available treatments and the utility of current guidance for the management of UF and endometriosis
- Integrate the current evidence surrounding GnRH antagonists into individualized management plans for patients with UF or endometriosis
- Incorporate patient preferences and shared decision making into personalized treatment plans for patients with UF or endometriosis
Accreditation and Credit Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This nursing activity has been approved for up to 0.75 contact hour.
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provider(s)/Educational Partner(s)
Provided by Med-IQ.
Commercial Support
This activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Activity Planners
Jessica Kimball, CST, MBA
Clinical Learning StrategistSara Samuel, MSc, MPhil, MS
Clinical Content Manager
Med-IQ
Baltimore, MDLarissa Picard-Broussard
CME Coordinator
Med-IQ
Baltimore, MDNikki Berry
Director, Accreditation
Med-IQ
Baltimore, MDKathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MIMedium/Method of Participation
This is a 0.75-credit CME/CE activity. To receive credit, read the introductory CME/CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: October 18, 2022
Expiration Date: October 17, 2023
Estimated Time to Complete This Activity: 45 minutesDrug/Product usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date:
Related
References
Show more
Recommended
Details
Presenters
Related
Comments
Recommended
Overview
Uterine fibroids and endometriosis are common gynecologic diseases that often cause pain, distress, and decreased quality of life. Unfortunately, they are often dismissed by clinicians as minor conditions. Traditional treatment options have included surgery, hormone therapy, radiation, and medical therapies. But now, gonadotropin-releasing hormone (GnRH) antagonists are proving to be an effective and well-tolerated alternative to invasive procedures. This real-world simulation reviews these emerging therapies and approaches for aligning patient priorities and desires with individualized treatment options.
Disclosure of Conflicts of Interest
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Erin T. Carey, MD, MSCR
Receipt of intellectual property right/patent holder: Patent applications for vestibulodynia and myofascial pelvic pain through UNC
Other: Served as an expert witness for pelvic pain and surgical complicationsErica E. Marsh, MD, MSCI, FACOG
Consulting fees/advisory boards: Myovant Sciences Ltd, Pfizer IncThe peer reviewers and activity planners have no financial relationships to disclose.
Target Audience
This activity is intended for obstetrician-gynecologists, primary care physicians, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with uterine fibroids and/or endometriosis.
Learning Objectives
Upon completion, participants should be able to:
- Recognize the signs, symptoms, patient characteristics, and comorbidities that are associated with UF and endometriosis
- Evaluate the benefits and limitations of available treatments and the utility of current guidance for the management of UF and endometriosis
- Integrate the current evidence surrounding GnRH antagonists into individualized management plans for patients with UF or endometriosis
- Incorporate patient preferences and shared decision making into personalized treatment plans for patients with UF or endometriosis
Accreditation and Credit Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This nursing activity has been approved for up to 0.75 contact hour.
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provider(s)/Educational Partner(s)
Provided by Med-IQ.
Commercial Support
This activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Activity Planners
Jessica Kimball, CST, MBA
Clinical Learning StrategistSara Samuel, MSc, MPhil, MS
Clinical Content Manager
Med-IQ
Baltimore, MDLarissa Picard-Broussard
CME Coordinator
Med-IQ
Baltimore, MDNikki Berry
Director, Accreditation
Med-IQ
Baltimore, MDKathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MIMedium/Method of Participation
This is a 0.75-credit CME/CE activity. To receive credit, read the introductory CME/CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: October 18, 2022
Expiration Date: October 17, 2023
Estimated Time to Complete This Activity: 45 minutesDrug/Product usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date:
Related
References
Show more
Facebook Comments